➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Boehringer Ingelheim
Colorcon
Dow
Harvard Business School

Last Updated: September 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR INSULIN DEGLUDEC

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Insulin Degludec

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00611884 ↗ Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes Completed Novo Nordisk A/S Phase 2 2008-01-01 This trial is conducted in Africa, Asia and North America. The aim of this trial is to compare two insulin degludec (NN1250, SIBA) formulations with each other and with insulin glargine, all in combination with metformin in insulin naive subjects with type 2 diabetes.
NCT00612040 ↗ Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes Completed Novo Nordisk A/S Phase 2 2008-01-01 This trial is conducted in Europe, Oceania and the United States of America (USA). The aim of this trial is to compare two NN1250 (insulin degludec) formulations with each other and with insulin glargine, all in combination with insulin aspart in subjects with type 1 diabetes.
NCT00613951 ↗ Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes Completed Novo Nordisk A/S Phase 2 2008-01-01 This trial is conducted in Europe. The aim of this trial is to compare two NN5401 (Soluble Insulin Analogue Combination [SIAC], insulin degludec/insulin aspart) formulations with each other and with biphasic insulin aspart 30, all in combination with metformin in insulin naive subjects with type 2 diabetes.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Insulin Degludec

Condition Name

Condition Name for Insulin Degludec
Intervention Trials
Diabetes 115
Diabetes Mellitus, Type 2 77
Diabetes Mellitus, Type 1 46
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Insulin Degludec
Intervention Trials
Diabetes Mellitus 143
Diabetes Mellitus, Type 2 92
Diabetes Mellitus, Type 1 60
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Insulin Degludec

Trials by Country

Trials by Country for Insulin Degludec
Location Trials
China 109
Germany 69
India 59
Canada 48
South Africa 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Insulin Degludec
Location Trials
California 56
Texas 55
Florida 51
North Carolina 44
New York 41
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Insulin Degludec

Clinical Trial Phase

Clinical Trial Phase for Insulin Degludec
Clinical Trial Phase Trials
Phase 4 18
Phase 3 70
Phase 2 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Insulin Degludec
Clinical Trial Phase Trials
Completed 99
Not yet recruiting 32
Recruiting 22
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Insulin Degludec

Sponsor Name

Sponsor Name for Insulin Degludec
Sponsor Trials
Novo Nordisk A/S 133
Eli Lilly and Company 11
Sanofi 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Insulin Degludec
Sponsor Trials
Industry 153
Other 37
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Moodys
Baxter
Johnson and Johnson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.